{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:59:04Z","timestamp":1757624344772,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jacig.2023.100186","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T22:14:38Z","timestamp":1699308878000},"page":"100186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin: A\u00a0potential adjunct for treatment of systemic mastocytosis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-2190","authenticated-orcid":false,"given":"Joseph H.","family":"Butterfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Bartemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2023.100186_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.712200","article-title":"Comparison of clinical efficacy and safety of metformin sustained-release tablet (II) (Dulening) and metformin tablet (Glucophage) in treatment of type 2 diabetes mellitus","volume":"12","author":"Guo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacig.2023.100186_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1872-034X.2012.01007.x","article-title":"In\u00a0vitro and in\u00a0vivo anti tumoral action of metformin on hepatocellular carcinoma","volume":"42","author":"Qu","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jacig.2023.100186_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070010","article-title":"Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells","volume":"8","author":"Saito","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacig.2023.100186_bib4","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacig.2023.100186_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.urolonc.2021.05.020","article-title":"Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED)","volume":"39","author":"Alghandour","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.jacig.2023.100186_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","article-title":"Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in\u00a0vivo","volume":"13","author":"Rattan","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.jacig.2023.100186_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1535-7163.MCT-11-0594","article-title":"The antidiabetic drug metformin inhibits gastric cancer cell proliferation in\u00a0vitro and in\u00a0vivo","volume":"11","author":"Kato","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jacig.2023.100186_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-017-0701-0","article-title":"Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer","volume":"16","author":"Chen","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jacig.2023.100186_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2553","article-title":"Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma. A\u00a0phase 2 randomized clinical trial","volume":"5","author":"Arrieta","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jacig.2023.100186_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1574892816666210208232251","article-title":"Targeting cancer stem cells with repurposed drugs to improve current therapies","volume":"16","author":"Fong","year":"2021","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.jacig.2023.100186_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2174\/1871520620666200918102642","article-title":"The chemosensitizing role of metformin in anti-cancer therapy","volume":"21","author":"Tang","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.jacig.2023.100186_bib12","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","article-title":"Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types","volume":"71","author":"Iliopoulos","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacig.2023.100186_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3892\/ijo.2018.4662","article-title":"Mechanisms of metformin\u2019s anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma","volume":"54","author":"Suzuki","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jacig.2023.100186_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-010-1072-z","article-title":"Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells","volume":"128","author":"Berstein","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacig.2023.100186_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/cells9051155","article-title":"Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity","volume":"9","author":"Gronningsaeter","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jacig.2023.100186_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/cancers14030486","article-title":"High metabolic dependence on oxidative phosphorylation drives sensitivity to metformin treatment in MLL\/AF9 acute myeloid leukemia","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jacig.2023.100186_bib17","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","article-title":"Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.jacig.2023.100186_bib18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/10781552221077254","article-title":"Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia","volume":"28","author":"Pokorny","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jacig.2023.100186_bib19","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacig.2023.100186_bib20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacig.2023.100186_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.769","article-title":"Concise review: cancer stem cells and minimal residual disease","volume":"30","author":"Ghiaur","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.jacig.2023.100186_bib22","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/s41375-019-0460-6","article-title":"Identification of a leukemia-initiating stem cell in human mast cell leukemia","volume":"33","author":"Eisenwort","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jacig.2023.100186_bib23","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1088\/0031-9155\/49\/16\/021","article-title":"Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas","volume":"49","author":"Macu","year":"2004","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.jacig.2023.100186_bib24","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.jacig.2023.100186_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1, and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jacig.2023.100186_bib26","first-page":"686","article-title":"Mastocytosis: a disease of the hematopoietic stem cell","volume":"105","author":"Horny","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jacig.2023.100186_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","article-title":"Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis","volume":"43","author":"Grootens","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacig.2023.100186_bib28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3324\/haematol.2018.195867","article-title":"Preclinical human models and emerging therapeutics for advanced systemic mastocytosis","volume":"103","author":"Arock","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jacig.2023.100186_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.jacig.2023.100186_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacig.2023.100186_bib31","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacig.2023.100186_bib32","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jacig.2023.100186_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2023.100186_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106383","article-title":"Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase","volume":"94","author":"Saito","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.jacig.2023.100186_bib35","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.2147\/DMSO.S286430","article-title":"Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus","volume":"13","author":"Zhang","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jacig.2023.100186_bib36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Baily","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacig.2023.100186_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jacig.2023.100186_bib38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jacig.2023.100186_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1185\/03007991003738063","article-title":"Avoiding hypoglycemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy","volume":"26","author":"Barnett","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacig.2023.100186_bib40","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.4161\/cc.20770","article-title":"Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells","volume":"11","author":"Pan","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jacig.2023.100186_bib41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an anti-diabetic drug to target leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacig.2023.100186_bib42","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3892\/or.2014.3151","article-title":"Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines","volume":"31","author":"Ling","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jacig.2023.100186_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932300111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277282932300111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:13:46Z","timestamp":1757423626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277282932300111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S277282932300111X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100186","relation":{},"ISSN":["2772-8293"],"issn-type":[{"type":"print","value":"2772-8293"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin: A\u00a0potential adjunct for treatment of systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100186"}}